SPHERA FUNDS MANAGEMENT LTD. - Q4 2009 holdings

Add to watchlist

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
No holdings reported for quarter Q4 2009
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
TEVA PHARMACEUTICAL-SP ADR39Q2 20248.4%
MERCK & CO INC NEW38Q2 20248.4%
NICE Systems Ltd30Q2 20244.4%
BIOGEN INC29Q2 20246.7%
PFIZER INC28Q2 20249.2%
SAREPTA THERAPEUTICS INC28Q2 20243.2%
JOHNSON & JOHNSON27Q2 20248.0%
AMICUS THERAPEUTICS INC26Q2 20224.3%
SYNDAX PHARMACEUTICALS INC25Q2 20243.9%
ASTRAZENECA PLC24Q2 20247.8%

View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.

Latest significant ownerships (13-D/G)
SPHERA FUNDS MANAGEMENT LTD. Q4 2009 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Skye Bioscience, Inc.February 08, 20241,301,5185.4%
Inozyme Pharma, Inc.February 05, 20241,562,9072.5%
Jasper Therapeutics, Inc.February 05, 20247,130,6256.4%
Praxis Precision Medicines, Inc.February 05, 2024328,9863.7%
ProMIS Neurosciences Inc.February 05, 20241,892,47410.0%
Cyclacel Pharmaceuticals, Inc.February 06, 2023250,0002.0%
Altimmune, Inc.February 14, 20221,244,2413.1%
Allot Ltd.February 16, 20211,129,0543.2%
Larimar Therapeutics, Inc.February 16, 2021? ?
Neos Therapeutics, Inc.February 16, 2021? ?

View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.

Latest filings
TypeFiled
N-PX2024-08-29
SC 13G2024-08-20
13F-HR2024-08-14
13F-HR2024-05-15
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G2024-02-08
SC 13G/A2024-02-05
SC 13G/A2024-02-05
SC 13G/A2024-02-05

View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.

All filings

View complete filings history.

Compare quarters

Export SPHERA FUNDS MANAGEMENT LTD.'s holdings

CSVXLS